Optimizing clozapine treatment

Acta Psychiatrica Scandinavica

Volumn 123, Issue 6, 2011, Pages 411-422

  Nielsen, J ^a,b   Damkier, P ^c   Lublin, H ^d   Taylor, D ^e,f  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b Maximum Security Unit   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d University Psychiatric Center Glostrup   (Denmark)

^e SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^f KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antipsychotic; Augmentation; Clozapine; Schizophrenia; Treatment resistant

Indexed keywords

AMISULPRIDE; AMITRIPTYLINE; ATROPINE; BENZATROPINE MESILATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOMIPRAMINE; CLONIDINE; CLOZAPINE; DESMOPRESSIN; DIPHENHYDRAMINE; FLUDROCORTISONE; FLUOXETINE; FLUVOXAMINE; IPRATROPIUM BROMIDE; LAMOTRIGINE; LAXATIVE; METHYLPHENIDATE; MODAFINIL; NEUROLEPTIC AGENT; PHYSOSTIGMINE; PIRENZEPINE; PLACEBO; PROPANTHELINE BROMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SCOPOLAMINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID;

ADD ON THERAPY; AGRANULOCYTOSIS; ANTICHOLINERGIC DISCONTINUATION SYNDROME; CARDIOMYOPATHY; CLINICAL TRIAL; CONSTIPATION; DELIRIUM; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; FLU LIKE SYNDROME; GOLD STANDARD; HUMAN; HYPERSALIVATION; LOW DRUG DOSE; MEDLINE; METABOLIC SYNDROME X; MYOCARDITIS; NEUTROPENIA; NOCTURNAL ENURESIS; OBSESSIVE COMPULSIVE DISORDER; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PSYCHOSIS; REBOUND PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SHOCK; SIDE EFFECT; SINUS TACHYCARDIA; TREATMENT RESPONSE;

ANTIPSYCHOTIC AGENTS; CALCIUM CHANNEL BLOCKERS; CENTRAL NERVOUS SYSTEM DISEASES; CLOZAPINE; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG THERAPY, COMBINATION; ELECTROCONVULSIVE THERAPY; HEART DISEASES; HUMANS; SCHIZOPHRENIA; TREATMENT OUTCOME; TRIAZINES;

EID: 79955956495     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2011.01710.x     Document Type: Review

References (160)

1. NICE. Schizophrenia core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. 2009 Available at: (updated 2009; cited 29 September 2010).
2. Ritsner M, Ponizovsky A, Endicott J et al. The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic study. Eur Neuropsychopharmacol 2002;12:31-38.
3. Pantelis C, Lambert TJ. Managing patients with 'treatment-resistant' schizophrenia. Med J Aust 2003;178(Suppl):S62-S66.
4. Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. Biol Psychiatry 2001;50:898-911.
5. Pilling S, Bebbington P, Kuipers E et al. Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behaviour therapy. Psychol Med 2002;32:763-782.
6. Pilling S, Bebbington P, Kuipers E et al. Psychological treatments in schizophrenia: II. Meta-analyses of randomized controlled trials of social skills training and cognitive remediation. Psychol Med 2002;32:783-791.
7. Sensky T, Turkington D, Kingdon D et al. A randomized controlled trial of cognitive-behavioral therapy for persistent symptoms in schizophrenia resistant to medication. Arch Gen Psychiatry 2000;57:165-172.
8. Penn DL, Mueser KT, Tarrier N et al. Supportive therapy for schizophrenia: possible mechanisms and implications for adjunctive psychosocial treatments. Schizophr Bull 2004;30:101-112.
9. Young CR, Bowers MB Jr, Mazure CM. Management of the adverse effects of clozapine. Schizophr Bull 1998;24:381-390.
10. Aronowitz JS, Safferman AZ, Lieberman JA. Management of clozapine-induced enuresis. Am J Psychiatry 1995;152:472.
11. Praharaj SK, Arora M, Gandotra S. Clozapine-induced sialorrhea: pathophysiology and management strategies. Psychopharmacology (Berl) 2006;185:265-273.
12. Safferman A, Lieberman JA, Kane JM, Szymanski S, Kinon B. Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 1991;17:247-261.
13. Munro J, O'sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R. Active monitoring of 12, 760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry 1999;175:576-580.
14. Michelsen JW, Meyer JM. Cardiovascular effects of antipsychotics. Expert Rev Neurother 2007;7:829-839.
15. Nielsen J, Foldager L, Meyer JM. Increased use of antibiotics in patients treated with clozapine. Eur Neuropsychopharmacol 2009;19:483-486.
16. Nielsen J, Boysen A. Clozapine treatment associated with increased risk of acute myeloid leukemia (AML). Schizophr Res 2010;123:270-272.
17. Henderson DC, Nguyen DD, Copeland PM et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 2005;66:1116-1121.
18. Lieberman JA, Safferman AZ, Pollack S et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994;151:1744-1752.
19. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796.
20. Meltzer HY, Alphs L, Green AI et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003;60:82-91.
21. Volavka J, Czobor P, Nolan K et al. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychopharmacol 2004;24:225-228.
22. Schulte PF, Cohen D, Bogers JP, Van Dijk D, Bakker B. A Dutch guideline for the use of clozapine. Aust N Z J Psychiatry 2010;44:1055-1056.
23. Cooper TB. Clozapine plasma level monitoring: current status. Psychiatr Q 1996;67:297-311.
24. Khan AY, Preskorn SH. Examining concentration-dependent toxicity of clozapine: role of therapeutic drug monitoring. J Psychiatr Pract 2005;11:289-301.
25. Guitton C, Kinowski JM, Abbar M, Chabrand P, Bressolle F. Clozapine and metabolite concentrations during treatment of patients with chronic schizophrenia. J Clin Pharmacol 1999;39:721-728.
26. Bell R, Mclaren A, Galanos J, Copolov D. The clinical use of plasma clozapine levels. Aust N Z J Psychiatry 1998;32:567-574.
27. Raaska K, Neuvonen PJ. Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia. Eur J Clin Pharmacol 2000;56:585-589.
28. Schulte P. What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia. Clin Pharmacokinet 2003;42:607-618.
29. Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991;148:231-235.
30. Potkin SG, Bera R, Gulasekaram B et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 1994;55(Suppl B):133-136.
31. Kronig MH, Munne RA, Szymanski S et al. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry 1995;152:179-182.
32. Vanderzwaag C, Mcgee M, Mcevoy JP, Freudenreich O, Wilson WH, Cooper TB. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 1996;153:1579-1584.
33. Risby ED, Epstein CM, Jewart RD et al. Clozapine-induced EEG abnormalities and clinical response to clozapine. J Neuropsychiatry Clin Neurosci 1995;7:466-470.
34. Spina E, Avenoso A, Facciola G et al. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. Int Clin Psychopharmacol 1998;13:141-145.
35. Stahl SM. How to dose a psychotropic drug: beyond therapeutic drug monitoring to genotyping the patient. Acta Psychiatr Scand 2010;122:440-441.
36. Raggi MA, Mandrioli R, Sabbioni C, Pucci V. Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions. Curr Med Chem 2004;11:279-296.
37. Kaladjian A, Bery B, Deturmeny E, Bruguerolle B. Clozapine monitoring: plasma or serum levels? Ther Drug Monit 1999;21:327-329.
38. Hermida J, Paz E, Tutor JC. Clozapine and norclozapine concentrations in serum and plasma samples from schizophrenic patients. Ther Drug Monit 2008;30:41-45.
39. Olesen OV, Thomsen K, Jensen PN et al. Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: a cross-sectional study. Psychopharmacology (Berl) 1995;117:371-378.
40. Dumortier G, Mahe V, Pons D, Zerrouk A, Januel D, Degrassat K. Clonic seizure associated with high clozapine plasma level. J Neuropsychiatry Clin Neurosci 2001;13:302-303.
41. Simpson GM, Cooper TA. Clozapine plasma levels and convulsions. Am J Psychiatry 1978;135:99-100.
42. Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology 1991;41:369-371.
43. Freudenreich O, Weiner RD, Mcevoy JP. Clozapine-induced electroencephalogram changes as a function of clozapine serum levels. Biol Psychiatry 1997;42:132-137.
44. Knoll JLT. Clozapine-related speech disturbance. J Clin Psychiatry 1997;58:219-220.
45. Pisani F, Oteri G, Costa C, Di Raimondo G, Di Perri R. Effects of psychotropic drugs on seizure threshold. Drug Saf 2002;25:91-110.
46. Treves IA, Neufeld MY. EEG abnormalities in clozapine-treated schizophrenic patients. Eur Neuropsychopharmacol 1996;6:93-94.
47. Gross A, Joutsiniemi SL, Rimon R, Appelberg B. Clozapine-induced QEEG changes correlate with clinical response in schizophrenic patients: a prospective, longitudinal study. Pharmacopsychiatry 2004;37:119-122.
48. Silvestri RC, Bromfield EB, Khoshbin S. Clozapine-induced seizures and EEG abnormalities in ambulatory psychiatric patients. Ann Pharmacother 1998;32:1147-1151.
49. Malow BA, Reese KB, Sato S et al. Spectrum of EEG abnormalities during clozapine treatment. Electroencephalogr Clin Neurophysiol 1994;91:205-211.
50. Centorrino F, Price BH, Tuttle M et al. EEG abnormalities during treatment with typical and atypical antipsychotics. Am J Psychiatry 2002;159:109-115.
51. Welch J, Manschreck T, Redmond D. Clozapine-induced seizures and EEG changes. J Neuropsychiatry Clin Neurosci 1994;6:250-256.
52. Neufeld MY, Rabey JM, Orlov E, Korczyn AD. Electroencephalographic findings with low-dose clozapine treatment in psychotic Parkinsonian patients. Clin Neuropharmacol 1996;19:81-86.
53. Knott V, Labelle A, Jones B, Mahoney C. Quantitative EEG in schizophrenia and in response to acute and chronic clozapine treatment. Schizophr Res 2001;50:41-53.
54. Gunther W, Baghai T, Naber D, Spatz R, Hippius H. EEG alterations and seizures during treatment with clozapine. A retrospective study of 283 patients. Pharmacopsychiatry 1993;26:69-74.
55. Chung SJ, Jeong SH, Ahn YM et al. A retrospective study of clozapine and electroencephalographic abnormalities in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:139-144.
56. Sajatovic M, Meltzer HY. Clozapine-induced myoclonus and generalized seizures. Biol Psychiatry 1996;39:367-370.
57. Rajji TK, Uchida H, Ismail Z et al. Clozapine and global cognition in schizophrenia. J Clin Psychopharmacol 2010;30:431-436.
58. Adler G, Grieshaber S, Faude V, Thebaldi B, Dressing H. Clozapine in patients with chronic schizophrenia: serum level, EEG and memory performance. Pharmacopsychiatry 2002;35:190-194.
59. Ronaldson KJ, Taylor AJ, Fitzgerald PB, Topliss DJ, Elsik M, Mcneil JJ. Diagnostic characteristics of clozapine-induced myocarditis identified by an analysis of 38 cases and 47 controls. J Clin Psychiatry 2010;71:976-981.
60. Kilian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999;354:1841-1845.
61. Liu HC, Chang WH, Wei FC, Lin SK, Jann MW. Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients. Ther Drug Monit 1996;18:200-207.
62. Ulrich S, Baumann B, Wolf R et al. Therapeutic drug monitoring of clozapine and relapse--a retrospective study of routine clinical data. Int J Clin Pharmacol Ther 2003;41:3-13.
63. Spina E, Avenoso A, Facciola G et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology (Berl) 2000;148:83-89.
64. Preskorn SH, Fast GA. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. J Clin Psychiatry 1991;52(Suppl):23-33.
65. Sartorius A, Hewer W, Zink M, Henn FA. High-dose clozapine intoxication. J Clin Psychopharmacol 2002;22:91-92.
66. Trappler B, Kwong V, Leeman CP. Therapeutic effect of clozapine at an unusually high plasma level. Am J Psychiatry 1996;153:133-134.
67. Kramer I, Rauber-Luthy C, Kupferschmidt H, Krahenbuhl S, Ceschi A. Minimal dose for severe poisoning and influencing factors in acute human clozapine intoxication: a 13-year retrospective study. Clin Neuropharmacol 2010;33:230-234.
68. Choc MG, Lehr RG, Hsuan F et al. Multiple-dose pharmacokinetics of clozapine in patients. Pharm Res 1987;4:402-405.
69. Peacock L, Gerlach J. Clozapine treatment in Denmark: concomitant psychotropic medication and hematologic monitoring in a system with liberal usage practices. J Clin Psychiatry 1994;55:44-49.
70. Nielsen J, Dahm M, Lublin H, Taylor D. Psychiatrists' attitude towards and knowledge of clozapine treatment. J Psychopharmacol 2010;24:965-971.
71. Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry 2007;18:39-60.
72. Sassim N, Grohmann R. Adverse drug reactions with clozapine and simultaneous application of benzodiazepines. Pharmacopsychiatry 1988;21:306-307.
73. Borentain S, Millet B, Olie JP. Cardiac risk at the onset of treatment in patients treated with benzodiazepines and clozapine. Eur Psychiatry 2002;17:419-420.
74. Baker RW, Kinon BJ, Maguire GA, Liu H, Hill AL. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. J Clin Psychopharmacol 2003;23:342-348.
75. Donlon PT, Hopkin JT, Tupin JP, Wicks JJ, Wahba M, Meadow A. Haloperidol for acute schizophrenic patients. An evaluation of three oral regimens. Arch Gen Psychiatry 1980;37:691-695.
76. Mofsen R, Balter J. Case reports of the reemergence of psychotic symptoms after conversion from brand-name clozapine to a generic formulation. Clin Ther 2001;23:1720-1731.
77. Kluznik JC, Walbek NH, Farnsworth MG, Melstrom K. Clinical effects of a randomized switch of patients from clozaril to generic clozapine. J Clin Psychiatry 2001;5:14-17. discussion 23-4.
78. Alvarez CA, Mascarenas C, Timmerman I. Increasing psychosis in a patient switched from clozaril to generic clozapine. Am J Psychiatry 2006;163:746.
79. Lam YW, Ereshefsky L, Toney GB, Gonzales C. Branded versus generic clozapine: bioavailability comparison and interchangeability issues. J Clin Psychiatry 2001;5:18-22. discussion 3-4.
80. Tassaneeyakul W, Kittiwattanagul K, Vannaprasaht S et al. Steady-state bioequivalence study of clozapine tablet in schizophrenic patients. J Pharm Pharm Sci 2005;8:47-53.
81. Paton C. Generic clozapine: outcomes after switching formulations. Br J Psychiatry 2006;189:184-185.
82. Alessi-Severini S, Honcharik PL, Simpson KD, Eleff MK, Collins DM. Evaluation of an interchangeability switch in patients treated with clozapine: a retrospective review. J Clin Psychiatry 2006;67:1047-1054.
83. Sajbel TA, Carter GW, Wiley RB. Converting patients from brand-name clozapine to generic clozapine. Ann Pharmacother 2001;35:281-284.
84. Healy DJ, Taylor S, Goldman M, Barry K, Blow F, Milner KK. Clinical equivalence of generic clozapine. Community Ment Health J 2005;41:393-398.
85. Couchman L, Morgan PE, Spencer EP, Johnston A, Flanagan RJ. Plasma clozapine and norclozapine in patients prescribed different brands of clozapine (Clozaril, Denzapine, and Zaponex). Ther Drug Monit 2010;32:624-627.
86. Maccall C, Billcliff N, Igbrude W, Natynczuk S, Spencer E, Flanagan R. Clozapine: more than 900 mg/day may be needed. J Psychopharmacol 2009;23:206-210.
87. Fabrazzo M, La Pia S, Monteleone P et al. Fluvoxamine increases plasma and urinary levels of clozapine and its major metabolites in a time- and dose-dependent manner. J Clin Psychopharmacol 2000;20:708-710.
88. Taylor D. Pharmacokinetic interactions involving clozapine. Br J Psychiatry 1997;171:109-112.
89. Lieberman JA, Kane JM, Johns CA. Clozapine: guidelines for clinical management. J Clin Psychiatry 1989;50:329-338.
90. Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR. The side-effects of clozapine: a four year follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:537-544.
91. Buchanan RW, Kreyenbuhl J, Kelly DL et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010;36:71-93.
92. Shiovitz TM, Welke TL, Tigel PD et al. Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal. Schizophr Bull 1996;22:591-595.
93. Foster R, Olajide D. A case of clozapine-induced tonic-clonic seizures managed with valproate: implications for clinical care. J Psychopharmacol 2005;19:93-96.
94. Wong J, Delva N. Clozapine-induced seizures: recognition and treatment. Can J Psychiatry 2007;52:457-463.
95. Langosch JM, Trimble MR. Epilepsy, psychosis and clozapine. Hum Psychopharmacol 2002;17:115-119.
96. Muzyk A, Gala G, Kahn DA. Use of lamotrigine in a patient with a clozapine-related seizure. J Psychiatr Pract 2010;16:125-128.
97. Rosenthal MH, Bryant SL. Benefits of adjunct modafinil in an open-label, pilot study in patients with schizophrenia. Clin Neuropharmacol 2004;27:38-43.
98. Miller SC. Methylphenidate for clozapine sedation. Am J Psychiatry 1996;153:1231-1232.
99. Centorrino F, Albert MJ, Drago-Ferrante G, Koukopoulos AE, Berry JM, Baldessarini RJ. Delirium during clozapine treatment: incidence and associated risk factors. Pharmacopsychiatry 2003;36:156-160.
100. Schuster P, Gabriel E, Kufferle B, Strobl G, Karobath M. Reversal by physostigmine of clozapine-induced delirium. Clin Toxicol 1977;10:437-441.
101. Lin SK, Su SF, Pan CH. Higher plasma drug concentration in clozapine-treated schizophrenic patients with side effects of obsessive/compulsive symptoms. Ther Drug Monit 2006;28:303-307.
102. Maccabe JH, Marks IM, Murray RM. Behavior therapy attenuates clozapine-induced obsessions and compulsions. J Clin Psychiatry 2002;63:1179-1180.
103. Poyurovsky M, Weizman A, Weizman R. Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment. CNS Drugs 2004;18:989-1010.
104. Stryjer R, Timinsky I, Reznik I, Weizman A, Spivak B. Beta-adrenergic antagonists for the treatment of clozapine-induced sinus tachycardia: a retrospective study. Clin Neuropharmacol 2009;32:290-292.
105. Low PA, Singer W. Management of neurogenic orthostatic hypotension: an update. Lancet Neurol 2008;7:451-458.
106. Testani M Jr. Clozapine-induced orthostatic hypotension treated with fludrocortisone. J Clin Psychiatry 1994;55:497-498.
107. Lieberman JA 3rd. Managing anticholinergic side effects. Prim Care Companion. J Clin Psychiatry 2004;6:20-23.
108. Nielsen J, Meyer JM. Risk Factors for Ileus in Patients with Schizophrenia. Schizophr Bull 2010 November 26. [Epub ahead of print].
109. Palmer SE, Mclean RM, Ellis PM, Harrison-Woolrych M. Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry 2008;69:759-768.
110. Steingard S. Use of desmopressin to treat clozapine-induced nocturnal enuresis. J Clin Psychiatry 1994;55:315-316.
111. Comley C, Galletly C, Ash D. Use of atropine eye drops for clozapine induced hypersalivation. Aust N Z J Psychiatry 2000;34:1033-1034.
112. Freudenreich O, Beebe M, Goff DC. Clozapine-induced sialorrhea treated with sublingual ipratropium spray: a case series. J Clin Psychopharmacol 2004;24:98-100.
113. Copp PJ, Lament R, Tennent TG. Amitriptyline in clozapine-induced sialorrhoea. Br J Psychiatry 1991;159:166.
114. Croissant B, Hermann D, Olbrich R. Reduction of side effects by combining clozapine with amisulpride: case report and short review of clozapine-induced hypersalivation-a case report. Pharmacopsychiatry 2005;38:38-39.
115. Praharaj SK, Verma P, Roy D, Singh A. Is clonidine useful for treatment of clozapine-induced sialorrhea? J Psychopharmacol 2005;19:426-428.
116. Bourgeois JA, Drexler KG, Hall MJ. Hypersalivation and clozapine. Hosp Community Psychiatry 1991;42:1174.
117. Kahl KG, Trillenberg P, Kordon A, Lencer R, Klein C, Hagenah J. [Pharmacological strategies for clozapine-induced hypersalivation: treatment with botulinum toxin B in one patient and review of the literature]. Nervenarzt 2005;76:205-208.
118. Gaftanyuk O, Trestman RL. Scolpolamine patch for clozapine-induced sialorrhea. Psychiatr Serv 2004;55:318.
119. Schneider B, Weigmann H, Hiemke C, Weber B, Fritze J. Reduction of clozapine-induced hypersalivation by pirenzepine is safe. Pharmacopsychiatry 2004;37:43-45.
120. Fritze J, Elliger T. Pirenzepine for clozapine-induced hypersalivation. Lancet 1995;346:1034.
121. Syed R, Au K, Cahill C et al. Pharmacological interventions for clozapine-induced hypersalivation. Cochrane Database Syst Rev 2008;3:CD005579.
122. Wilkins-Ho M, Hollander Y. Toxic delirium with low-dose clozapine. Can J Psychiatry 1997;42:429-430.
123. Mcgurk SR, Green MF, Wirshing WC et al. Antipsychotic and anticholinergic effects on two types of spatial memory in schizophrenia. Schizophr Res 2004;68:225-233.
124. Zink M, Knopf U, Henn FA, Thome J. Combination of clozapine and amisulpride in treatment-resistant schizophrenia--case reports and review of the literature. Pharmacopsychiatry 2004;37:26-31.
125. Reinstein MJ, Sirotovskaya LA, Jones LE, Sangarapillai M, Chasanov MA. Effect of clozapine-quetiapine combination therapy on weight and glycaemic control - preliminary findings. Clin Drug Investig 1999;18:99-104.
126. Englisch S, Zink M. Combined antipsychotic treatment involving clozapine and aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1386-1392.
127. Whiskey E, Taylor D. Restarting clozapine after neutropenia: evaluating the possibilities and practicalities. CNS Drugs 2007;21:25-35.
128. Hagg S, Rosenius S, Spigset O. Long-term combination treatment with clozapine and filgrastim in patients with clozapine-induced agranulocytosis. Int Clin Psychopharmacol 2003;18:173-174.
129. Conus P, Nanzer N, Baumann P. An alternative to interruption of treatment in recurrent clozapine-induced severe neutropenia. Br J Psychiatry 2001;179:180.
130. Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naive schizophrenia patients. Neuropsychopharmacology 2010;35:1997-2004.
131. Wu RR, Zhao JP, Jin H et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 2008;299:185-193.
132. Baptista T, Rangel N, Fernandez V et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr Res 2007;93:99-108.
133. Dursun SM, Devarajan S. Clozapine weight gain, plus topiramate weight loss. Can J Psychiatry 2000;45:198.
134. Fleischhacker WW, Heikkinen ME, Olie JP et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 2010;13:1115-1125.
135. De Leon J, Diaz FJ, Josiassen RC, Cooper TB, Simpson GM. Weight gain during a double-blind multidosage clozapine study. J Clin Psychopharmacol 2007;27:22-27.
136. Stoner SC, Dahmen MM, Berges A, Petry WM. Augmentation of aripiprazole with low-dose clozapine. Pharmacotherapy 2007;27:1599-1602.
137. Klein C, Gordon J, Pollak L, Rabey JM. Clozapine in Parkinson's disease psychosis: 5-year follow-up review. Clin Neuropharmacol 2003;26:8-11.
138. Taylor DM, Smith L. Augmentation of clozapine with a second antipsychotic - a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatr Scand 2009;119:419-425.
139. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic Combinations vs Monotherapy in Schizophrenia: a Meta-analysis of Randomized Controlled Trials. Schizophr Bull 2009;35:443-457.
140. Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev 2009;3:CD006324.
141. Weiner E, Conley RR, Ball MP et al. Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology 2010;35:2274-2283.
142. Muscatello MR, Bruno A, Pandolfo G et al. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophr Res 2011;127:93-99.
143. Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry 1996;57:395-397.
144. Henderson DC, Goff DC, Connolly CE, Borba CP, Hayden D. Risperidone added to clozapine: impact on serum prolactin levels. J Clin Psychiatry 2001;62:605-608.
145. Chong SA, Tan CH, Lee HS. Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: two case reports. J Clin Psychopharmacol 1997;17:68-69.
146. Chan YC, Miller KM, Shaheen N, Votolato NA, Hankins MB. Worsening of psychotic symptoms in schizophrenia with addition of lamotrigine: a case report. Schizophr Res 2005;78:343-345.
147. Paton C, Whittington C, Barnes TR. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis. J Clin Psychopharmacol 2007;27:198-204.
148. Chang JS, Ahn YM, Park HJ et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008;69:720-731.
149. Mitsonis CI, Dimopoulos NP, Mitropoulos PA et al. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: an open-label pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:373-377.
150. Josiassen RC, Joseph A, Kohegyi E et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2005;162:130-136.
151. Honer WG, Thornton AE, Chen EY et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006;354:472-482.
152. Assion HJ, Reinbold H, Lemanski S, Basilowski M, Juckel G. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry 2008;41:24-28.
153. Shiloh R, Zemishlany Z, Aizenberg D et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry 1997;171:569-573.
154. Goff DC. Review: lamotrigine may be an effective treatment for clozapine resistant schizophrenia. Evid Based Ment Health 2009;12:111.
155. Tiihonen J, Wahlbeck K, Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res 2009;109:10-14.
156. Havaki-Kontaxaki BJ, Ferentinos PP, Kontaxakis VP, Paplos KG, Soldatos CR. Concurrent administration of clozapine and electroconvulsive therapy in clozapine-resistant schizophrenia. Clin Neuropharmacol 2006;29:52-56.
157. Tranulis C, Mouaffak F, Chouchana L et al. Somatic augmentation strategies in clozapine resistance--what facts? Clin Neuropharmacol 2006;29:34-44.
158. Taylor DM, Douglas-Hall P, Olofinjana B, Whiskey E, Thomas A. Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-acting injection. Br J Psychiatry 2009;194:165-167.
159. Nielsen J, Le Quach P, Emborg C, Foldager L, Correll CU. 10-Year trends in the treatment and outcomes of patients with first-episode schizophrenia. Acta Psychiatr Scand 2010;122:356-366.
160. Mcevoy JP, Lieberman JA, Stroup TS et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163:600-610.